Press Releases 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
3.76 ^USD	+4.44%		0.00%	-11.94%

26/06	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
26/06	2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million	27/06	BU
2seventy bio to Participate in Upcoming Investor Conferences	23/05	BU
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress	08/05	BU
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	06/05	AQ
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	03/05	BU
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma	17/04	AQ
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy	08/04	AQ
2seventy bio : Corporate Presentation April 2024	01/04	PU
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron	01/04	BU
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors	21/03	BU
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?	18/03	PR
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	18/03	AQ
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress	05/03	BU
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	04/03	AQ
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	01/03	BU
2seventy bio to Participate in Upcoming Investor Conferences	06/02	BU
2seventy bio Announces New Strategic Path Forward	30/01	BU
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)	11/12	BU
2seventy bio Reiterates Commitment to Maximizing Shareholder Value	07/12	BU
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma	21/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 2seventy bio, Inc.

Equities

TSVT

US9013841070

Press Releases

Filters